Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2001
12/11/2001US6329520 Used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining doses of therapeutic agents that occupy many receptors
12/11/2001US6329449 Pulverulent rubber powders comprising modified fillers, processes for their preparation and their use
12/11/2001US6329432 Mesozeaxanthin formulations for treatment of retinal disorders
12/11/2001US6329430 Modulation of N-methyl-D-aspartate receptor responses with S-substituted derivatives of glutathione
12/11/2001US6329429 Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
12/11/2001US6329428 Therapy of disease of lower urinary tract system by using organic acid salt of (2-(4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl)ethyl)-dimeth ylsulfonium
12/11/2001US6329426 Method for treating ocular hypertension of glaucoma
12/11/2001US6329425 Modulation of inflammation related to Columnar epithelia
12/11/2001US6329422 Enhancing, stimulating chloride transport in epithelial cells; flavone or isoflavone or a stereoisomer thereof.
12/11/2001US6329421 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
12/11/2001US6329418 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
12/11/2001US6329417 Hepatitis C inhibitor tri-pepitides
12/11/2001US6329416 Administering to female of child bearing age for 28 consecutive days: first phase dosage of progestational agent; second phase of antiprogesin compound, and third phase of placebo for contraception
12/11/2001US6329415 Aromatic heterocyclic compounds as antiinflammatory agents
12/11/2001US6329414 Synthetic or naturally occurring phytonutrient of canthanaxin, limonene and/or vitamin a; cytoprotective selected from d- or l-histidine, racemic, non-racemic mixture, nutriceutically inert carrier, such as microcrystalline cellulose
12/11/2001US6329413 Stable oil-in-water emulsion; anionic or nonionic hydrophilic, water soluble emulsifier; galactoarabinan, polygalactose, or polyarabinose; skin protectant
12/11/2001US6329410 Water-base liquid preparation
12/11/2001US6329408 Hypocholesterolemic agents; optically pure
12/11/2001US6329407 Use of polycyclic thiazole systems for the treatment of obesity
12/11/2001US6329405 As ileal bile acid transporter inhibitor, for therapy of hyperlipemia
12/11/2001US6329404 Pharmaceutical composition
12/11/2001US6329403 Insulin sensitizer selected from pioglitazone, troglitazone, rosiglitazone, 4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy) benzyl)isoxazolidin-3,5-dione or salt, in combination with sibutramine or mazindol
12/11/2001US6329402 Heterocycle-containing carboxylic acid derivative and drug containing the same
12/11/2001US6329401 Enhancement of sleep with a tachykinin antagonist
12/11/2001US6329399 Antifungal amine derivatives and processing for producing the same
12/11/2001US6329398 Preemptive analgesic agent and methods of use
12/11/2001US6329397 Hydroxy pipecolate hydroxamic acid derivatives
12/11/2001US6329394 Medical use for tachykinin antagonists
12/11/2001US6329392 Substituted piperidines useful for the treatment of allergic diseases
12/11/2001US6329391 Antibiotics, bactericides using quinolones
12/11/2001US6329390 5-Bicycloindole compounds
12/11/2001US6329388 Thienopyridine compounds, their production and use
12/11/2001US6329387 Use of thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
12/11/2001US6329385 Antiinflammatory agents, antiarthritic agents, viral diseases and gastrointestinal disorders
12/11/2001US6329384 Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation
12/11/2001US6329382 Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine remedies/preventives for respiratory diseases
12/11/2001US6329380 Pyrimidine benzimidizazole, pyrimidineimidazole or pyridine imidazole compounds for anticancer agents or atherosclerosis
12/11/2001US6329379 Oligopeptides for inhibiting hepatitis
12/11/2001US6329374 Non-systemic control of parasites
12/11/2001US6329373 Metalloproteinase inhibitors
12/11/2001US6329372 Phenylalanine derivatives
12/11/2001US6329370 Cardiovascular disorders and tumor necrosis factor (hereinafter tnf.sub..alpha.), a cytokine with pro-inflammatory activity
12/11/2001US6329368 Endocrine modulation with positive modulators of AMPA type glutamate receptors
12/11/2001US6329366 Heterocyclic, piperidine, indole derivitives for treatment of nervous system disorders and serotonin antagonist
12/11/2001US6329364 Crystalline form of dihydro-2,3-benzodiazepine derivative
12/11/2001US6329363 Cephalosporin antibiotics
12/11/2001US6329362 Modulation cell adhesion the compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
12/11/2001US6329361 Hypoglycemic agents and stabilization
12/11/2001US6329360 Hetero-linked phenylglycinolamides
12/11/2001US6329358 Pharmaceutical composition suitable for stimulating the multiplication and growth of osteoblasts
12/11/2001US6329357 Therapeutically effective 1α, 25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases
12/11/2001US6329356 Phosphono-carboxylate compounds for treating amyloidosis
12/11/2001US6329355 Method for inhibiting the growth of cancers
12/11/2001US6329354 Administering bone active phosphonate, administering estrogen hormone
12/11/2001US6329352 Method and composition for treating sleep apnea
12/11/2001US6329351 Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
12/11/2001US6329350 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
12/11/2001US6329347 Anticarcinogenic agents using mycobacterium dna, delipidated, deproteinized cell walls
12/11/2001US6329345 13-membered azalides and their use as antibiotic agents
12/11/2001US6329344 Urea derivative of alkylene dioxyfuran ethers
12/11/2001US6329342 Treatment of congestive heart failure with growth hormone secretagogues
12/11/2001US6329339 Lactoferrin with glycyrrhizic acid as synergist
12/11/2001US6329199 A vector resistant to inactivation by human serum, produced in cells containing retroviral envelope protein sequence from feline endogenous virus, long terminal repeats sequences, signal and packaging sequences; for effective gene therapy
12/11/2001US6328998 Artherosclerosis, cardiovascular, anticoagulant, antiischemic
12/11/2001US6328995 Stable vitamin and/or carotenoid products in powder form and process for their production
12/11/2001US6328994 Orally disintegrable tablets
12/11/2001US6328993 Oral administration form for an acid liable active proton pump inhibitor
12/11/2001US6328992 Cannabinoid patch and method for cannabis transdermal delivery
12/11/2001US6328989 Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli
12/11/2001US6328984 Selective antibacterial composition
12/11/2001US6328983 Cosmetics, skin treatments
12/11/2001US6328979 Sustained release medicinal compositions
12/11/2001US6328970 Rapamycin position 27 conjugates
12/11/2001US6328957 Heat shock proteins and the treatment of tumors
12/11/2001US6328953 Polymeric derivatives of camptothecins
12/11/2001US6328855 Method for producing (+)-exo-6-phenyl-3-azabicyclo-[3.2.0]heptanes
12/11/2001CA2246014C Food supplements and methods comprising lipoic acid and creatine
12/11/2001CA2226292C Substituted benzolactam compounds as substance p antagonists
12/11/2001CA2218643C Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
12/11/2001CA2215234C Composition containing amlodipine, or its salt and an ace inhibitor
12/11/2001CA2213108C 2-aminobenzazapine derivatives
12/11/2001CA2205033C Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas as 5-lipoxygenase inhibitors
12/11/2001CA2193849C Method for treating anxiety
12/11/2001CA2136094C Methods and compositions for increasing the sensitivity of a cell to a dna damaging agent
12/11/2001CA2053709C Piperazine derivatives
12/11/2001CA1341325C Triazole antifungal agents
12/09/2001CA2347337A1 Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
12/09/2001CA2311084A1 C8-substituted purine nucleotide analogs and their use as inhibitors of nucleoside triphosphate diphosphohydrolases
12/08/2001CA2349776A1 Novel crystalline forms of (3s-trans)-2-¬3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2h-1-benzopyran-7-yl|-4-(trifluoromethyl)-benzoic acid
12/08/2001CA2347316A1 Growth promoting pharmaceutical implant
12/06/2001WO2001092891A2 Regulating lipid levels via the zmax1 or hbm gene
12/06/2001WO2001092584A1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
12/06/2001WO2001092581A2 Compositions and methods for the therapy and diagnosis of ovarian cancer
12/06/2001WO2001092580A2 Lyophilizable and enhanced compacted nucleic acids
12/06/2001WO2001092565A2 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
12/06/2001WO2001092543A2 Improved methods of transfection
12/06/2001WO2001092542A2 Integrin-targeting vectors having enhanced transfection activity
12/06/2001WO2001092526A1 Human kcnq5 potassium channel, methods and compositions thereof
12/06/2001WO2001092513A1 METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
12/06/2001WO2001092331A2 Compositions and methods for the treatment of immune related diseases